Literature DB >> 1942401

Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.

A E Washington1, P Katz.   

Abstract

Pelvic inflammatory disease (PID) and its sequelae affect millions of women in the United States at substantial costs. To estimate these total costs annually and to determine payment sources, we analyzed data from local, state, and national sources. Direct costs for PID and PID-associated ectopic pregnancy and infertility were estimated to be $2.7 billion, and indirect costs were estimated to be $1.5 billion, for a total cost of $4.2 billion in 1990. Overall, private insurance covered the largest portion of the direct costs of PID (41%), followed by public payment sources (30%). However, the proportion of payments made by private insurance appears to be decreasing, while that by public payment sources is increasing. In the year 2000, costs associated with PID are projected to approach $10 billion if the current PID incidence persists, with an increasing proportion of this expense burdening public institutions. Prevention of PID is needed both to reduce human suffering and to contain rising costs.

Entities:  

Mesh:

Year:  1991        PMID: 1942401

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  31 in total

Review 1.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?

Authors:  I Simms; J M Stephenson
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

Review 2.  Vaginal douching: evidence for risks or benefits to women's health.

Authors:  Jenny L Martino; Sten H Vermund
Journal:  Epidemiol Rev       Date:  2002       Impact factor: 6.222

3.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

4.  Vaginal douching and adverse health effects: a meta-analysis.

Authors:  J Zhang; A G Thomas; E Leybovich
Journal:  Am J Public Health       Date:  1997-07       Impact factor: 9.308

5.  Comparison of Digene hybrid capture 2 and conventional culture for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens.

Authors:  Ling H Darwin; Allison P Cullen; Patrick M Arthur; Carole D Long; Kim R Smith; Jennifer L Girdner; Edward W Hook; Thomas C Quinn; Attila T Lorincz
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

6.  Estimating the direct costs of pelvic inflammatory disease in adolescents: a within-system analysis.

Authors:  Maria Trent; Jonathan M Ellen; Kevin D Frick
Journal:  Sex Transm Dis       Date:  2011-04       Impact factor: 2.830

7.  Cost effectiveness analysis of azithromycin and doxycycline for Chlamydia trachomatis infection in women: A Canadian perspective.

Authors:  F Marra; C A Marra; D M Patrick
Journal:  Can J Infect Dis       Date:  1997-07

8.  Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice.

Authors:  A E Jerse
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

9.  Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.

Authors:  S Pal; I Theodor; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 10.  Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin.

Authors:  Francesco Cappello; Everly Conway de Macario; Valentina Di Felice; Giovanni Zummo; Alberto J L Macario
Journal:  PLoS Pathog       Date:  2009-08-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.